2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z

Abstract Number: 002

Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression
Abstract Number: 005

Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Abstract Number: 065

Relationship Between Arthritis and Uveitis Disease Activity in Children with JIA
Abstract Number: 010

Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus: A Preliminary Investigation
Abstract Number: 084

Rheum to Improve: Patient-reported Transition Readiness in a Large Pediatric Rheumatology Clinic
Abstract Number: 083

Running out of Rheum: Where Are the Pediatric Rheumatology Faculty?

Jump to: View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

2023 Pediatric Rheumatology Symposium

Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression

Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study

Relationship Between Arthritis and Uveitis Disease Activity in Children with JIA

Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus: A Preliminary Investigation

Rheum to Improve: Patient-reported Transition Readiness in a Large Pediatric Rheumatology Clinic

Running out of Rheum: Where Are the Pediatric Rheumatology Faculty?